Frontiers in Oncology (Jun 2021)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy

  • Marion Grard,
  • Marion Grard,
  • Camille Chatelain,
  • Camille Chatelain,
  • Tiphaine Delaunay,
  • Tiphaine Delaunay,
  • Elvire Pons-Tostivint,
  • Elvire Pons-Tostivint,
  • Elvire Pons-Tostivint,
  • Jaafar Bennouna,
  • Jaafar Bennouna,
  • Jaafar Bennouna,
  • Jean-François Fonteneau,
  • Jean-François Fonteneau

DOI
https://doi.org/10.3389/fonc.2021.695770
Journal volume & issue
Vol. 11

Abstract

Read online

Homozygous deletion (HD) of the tumor suppressor gene CDKN2A is the most frequent genetic alteration in malignant pleural mesothelioma and is also frequent in non-small cell lung cancers. This HD is often accompanied by the HD of the type I interferons (IFN I) genes that are located closed to the CDKN2A gene on the p21.3 region of chromosome 9. IFN I genes encode sixteen cytokines (IFN-α, IFN-β…) that are implicated in cellular antiviral and antitumor defense and in the induction of the immune response. In this review, we discuss the potential influence of IFN I genes HD on thoracic cancers therapy and speak in favor of better taking these HD into account in patients monitoring.

Keywords